Erasca, Inc.
HealthcareNASDAQ:ERAS · NASDAQ Global Select
+$0.04 today
Vol 2.08M · Avg 6.95M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.3%
avg -29.7%
ROIC
-35.3%
avg -44.6%
ROA
-31.4%
avg -38.6%
Analysis
ROA is currently the strongest return metric at -31.4% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | $1.16M | — | 54 | $2.00M | 0.64% |
David Chacko | Chief Financial Officer & Chief Business Officer | $775,216.00 | — | 42 | $640,000.00 | 0.21% |
Shannon Morris | Chief Medical Officer | $772,700.00 | — | 56 | $0.00 | <0.01% |
Ebun S. Garner | Chief Legal Officer & Corporate Secretary | $607,440.00 | — | 54 | $25,076.00 | <0.01% |
Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | $93,181.00 | — | 68 | $96,000.00 | 0.03% |
Robert Shoemaker | Chief Scientific Officer | — | — | 45 | — | — |
Dawei Xuan | Senior Vice President of Clinical Pharmacology | — | — | — | — | — |
Alison Tjosvold Milhous | Senior Vice President of Accounting | — | — | 47 | — | — |
Chandra D. Lovejoy | Chief Regulatory Affairs Officer | — | — | 55 | — | — |
Minli Xie | Senior Vice President of Pharmaceutical Development & Operations | — | — | — | — | — |
Lisa Tesvich-Bonora | Chief People Officer | — | — | — | — | — |
Brian L. Baker | Senior Vice President of Finance | — | — | 59 | — | — |
Nik Chetwyn | Chief Operating Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$2.28M
Net Sentiment
$2.28M
Net selling
Most Active
Garner Ebun
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Garner Ebun Direct | Sell | 80.0K | $16.40 | $1,312,000.00 | |
| Mar 4, 2026 | Morris Shannon Direct | Sell | 20.0K | $15.04 | $300,760.00 | |
| Jan 7, 2026 | Garner Ebun Direct | Sell | 120.0K | $5.59 | $670,812.00 |
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $2.28M over the last 12 months. That adds up to net selling of $2.28M. Garner Ebun was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
Who manages ERAS?
Erasca, Inc. (ERAS) lists 13 active executives. The top listed executive is Michael D. Varney, Chairman of Research & Development, Scientific Advisory Board Member and Director.
Are ERAS insiders buying or selling?
Recent insider activity shows net buying of $102.89M.
Explore More
Continue the stock analysis
Jump to another research area for this company.